Hims & Hers: FTC suit widens to seven states
- Bad news: The FTC suit grew from two states to seven, with state consumer-protection claims added, tilting settlement leverage towards plaintiffs.
- Mixed: Peptides+ launches at the end of November, but the chief financial officer says peptide revenue will be immaterial this year.
- Bad news: Branded weight-loss drugs have cut gross margin from 74% to 57%, and peptides cannot offset that soon.
Read the full notes
Thesis maintained, with a warning flag ⚠️. The regulatory thread has worsened another notch: the plaintiffs in the Federal Trade Commission (FTC) suit have grown from two states to seven (Arizona, Florida, Nebraska, Ohio and Wisconsin are new), and state consumer-protection claims have been added, tilting settlement leverage further towards the plaintiffs.
Read more
The real risk is not the $62.5 million accrued for a fine. It is that an injunction restricting the return of health data to advertising platforms would hurt acquisition efficiency when marketing resumes for the Q1 weight-loss season. The peptides line, Peptides+ (NAD+, sermorelin, glutathione and B12), launches at the end of November, while BPC-157 and TB-500 are on hold to avoid regulatory risk. The chief financial officer said clearly that peptide revenue will be immaterial this year. The direction is right (longevity and a growing store of health data), but in the short term it cannot offset the way branded weight-loss drugs have cut gross margin from 74% to 57%.
Brief ID
2026-11-11-hims-ftc-7states-peptides-plus-launch
Key evidence
- On 10 Nov the FTC filed an amended complaint in the federal court for the Northern District of California, approved by a 2-0 vote of the commission
- Five states join as co-plaintiffs: Arizona, Florida, Nebraska, Ohio and Wisconsin
- With Utah and California from the original 29 Jul suit, that makes seven states
- State consumer-protection claims are added to the existing charges under the FTC Act and the Restore Online Shoppers' Confidence Act
- The allegations are unchanged: (1) health information was passed to advertising platforms such as Meta and Snap as customer lists and website tracking events; (2) customers were charged for medication after the intake form but before seeing a doctor, subscriptions renewed automatically, and the cancel button was buried several pages deep
- The company says these are follow-on allegations and that it will defend itself vigorously
Show 10 more
- On 30 Oct the judge indicated that a dismissal of the suit is unlikely
- HIMS has accrued about $62.5 million for a fine
- Peptides+ launches at the end of November, starting with NAD+, sermorelin, glutathione and vitamin B12, with blood testing and ongoing clinical follow-up
- BPC-157, TB-500 and similar products will be added when the regulatory environment allows, and the company will make them in the US
- Chief financial officer Okupe said clearly that peptide revenue will be immaterial this year
- The first four are not among the six core products on the 30 Oct Federal Register enforcement-discretion list
- The 30 Oct Federal Register policy is enforcement discretion, not approval. Comments close on 13 Nov, and it can be withdrawn
- Branded weight-loss drugs have cut gross margin from 74% to 57%
- The company has deliberately scaled back marketing in Q4 and plans to resume it for the Q1 weight-loss season
- No new SEC EDGAR filings since the 10-Q and two 8-Ks of 9 Nov
Reporter
Our research team
Catalysts to watch
- The terms of any FTC settlement (whether an injunction restricts the return of health data to advertising platforms)
- Acquisition efficiency when marketing resumes for the Q1 weight-loss season
- The launch date for BPC-157 and TB-500 (depends on the final regulation after 13 Nov)
- Whether Q4 and Q1 results separately disclose peptide or longevity subscriber numbers
- Whether more states join the suit
Risks
- A wider group of seven plaintiff states tilts settlement leverage towards the plaintiffs
- If the injunction restricts returning health data to advertising platforms, acquisition efficiency will suffer directly
- The gross margin has been squeezed structurally from 74% to 57%, and peptides cannot offset it in the short term
- The peptides strategy is conservative: avoiding the enforcement-discretion risk on BPC-157 and TB-500 means no high-profile SKU for now
- The policy can be withdrawn, so the long-term rollout of peptides remains uncertain
Sources 6
- Federal Trade Commission press release (10 Nov)
- Reuters (9 Nov, 10 Nov)
- MLex
- HIMS Q3 call minutes
- Reuters interviews with chief executive Dudum and chief financial officer Okupe
- SEC EDGAR